Trial Profile

A Phase 2 Interventional, Multicenter, Randomized Open Label Study to Determine the Effective and Tolerable Dose of KAF156 and Lumefantrine Solid Dispersion Formulation in Combination, Given Once Daily for 1, 2 and 3-days to Adults and Children With Uncomplicated Plasmodium Falciparum Malaria

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 29 Nov 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ganaplacide (Primary) ; Lumefantrine (Primary) ; Artemether/lumefantrine
Indications Falciparum malaria
Focus Therapeutic Use
Sponsors Novartis; Novartis Healthcare; Novartis Pharma A.G.; Novartis Pharmaceuticals

23 Nov 2022 According to a Novartis media release, this trial receive funding from the European and Developing Countries Clinical Trials Partnership (EDCTP), which is supported by the European Union.
23 Nov 2022 Results presented in a Novartis Media Release.
05 Oct 2021 According to a Novartis media release, results from this study will be published in the New England Journal of Medicine.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com